Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Enrica Antonia Martino, Raffaella Pasquale, Isacco Ferrarini, Riccardo Moia, Andrea Visentin, Alessandro Sanna, Marina Motta, Massimo Moratti, Paolo Sportoletti, Annalisa Chiarenza, Alessandro Maggi, Valentina Zammit, Michele Merli, Idanna Innocenti, Claudia Giordano, Laura Nocilli, Massimiliano Postorino, Caterina Stelitano, Andrea Ferrario, Annamaria Frustaci, Stefania Scardino, Paola Anticoli Borza, Laura Ballotta, Salvatrice Mancuso, Gerardo Musuraca, Anna Mele, Sara Galimberti, Gioacchino Catania, Annamaria Giordano, Ilaria Angeletti, Luana Schiattone, Elsa Pennese, Rosanna Miccolis, Angelo Fama, Giulio Giordano, Catello Califano, Ernesto Vigna, Antonella Bruzzese, Giuliana Farina, Pietro Bulian, Giacomo Loseto, Barbara Pocali, Vanessa Innao, Piero Galieni, Vincenzo Ludovico Fraticelli, Candida Vitale, Azzurra Anna Romeo, Marco Rossi, Ilaria Scortechini, Federico Vozzella, Luigi Malandruccolo, Enrico Derenzini, Valentina di Martina, Roberto Marasca, Maria Ilaria Del Principe, Marta Coscia, Nicola Di Renzo, Luca Laurenti, Antonino Neri, Pellegrino Musto, Francesco Di Raimondo, Alessandra Tedeschi, Livio Trentin, Gianluca Gaidano, Fortunato Morabito, Valter Gattei, Massimo Gentile

Blood (2024) 144 (Supplement 1): 6794.

https://doi.org/10.1182/blood-2024-205354

Published: 2024

Journal Articles

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Blood (2024) 144 (Supplement 1): 3297.

https://doi.org/10.1182/blood-2024-198382

Published: 2024

Journal Articles

Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort

Blood (2023) 142 (Supplement 1): 3282.

https://doi.org/10.1182/blood-2023-186479

Published: 2023

Journal Articles

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Blood (2023) 142 (Supplement 1): 1680.

https://doi.org/10.1182/blood-2023-182347

Published: 2023

Journal Articles

Brentuximab Vedotin in the Treatment of Cutaneuous T Cell Lymphomas: A Multicenter, Retrospective, Case-Control Study from Italy

Erika Morsia, Vieri Grandi, Annagiulia Zizzari, Giacomo Loseto, Paolo Fava, Silvia Alberti Violetti, Alessandro Pileri, Alessandro Broccoli, Paola Vitiello, Antonello Sica, Luca Nassi, Cosimo Di Riamondo, Pietro Quaglino, Nicola Pimpinelli, Emilio Berti, Pier Luigi Zinzani, Serena Rupoli

Blood (2023) 142 (Supplement 1): 6111.

https://doi.org/10.1182/blood-2023-189116

Published: 2023

Journal Articles

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 1621.

https://doi.org/10.1182/blood-2023-181731

Published: 2023

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Blood (2023) 142 (Supplement 1): 737.

https://doi.org/10.1182/blood-2023-179169

Published: 2023

Journal Articles

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Blood (2023) 142 (Supplement 1): 4646.

https://doi.org/10.1182/blood-2023-186182

Published: 2023

Journal Articles

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

Carla Minoia, Davide Bavaro, Giacomo Loseto, Crescenza Pasciolla, Lucia Diella, Carmen Pelligrino, Valentina Totaro, Vito Spada, Michele Camporeale, Immacolata Attolico, Tommasina Perrone, Felice Clemente, Francesco di Gennaro, Pellegrino Musto, Attilio Guarini, Annalisa Saracino

Blood (2022) 140 (Supplement 1): 10967–10968.

https://doi.org/10.1182/blood-2022-168809

Published: 2022

Journal Articles

A Digital Gene-Expression Signature Supports Mediastinal Gray Zone Lymphoma Stratification within Classical Hodgkin or Primary Mediastinal B-Cell Lymphoma

Maria Carmela Vegliante, Grazia Gargano, Flavia Esposito, Giuseppina Opinto, Gian Maria Zaccaria, Susanna Anita Pappagallo, Paolo Mondelli, Giacomo Loseto, Anna Scattone, Elena Sabattini, Claudio Agostinelli, Valentina Tabanelli, Luca Nassi, Attilio Guarini, Stefano A Pileri, Sabino Ciavarella

Blood (2022) 140 (Supplement 1): 9312–9313.

https://doi.org/10.1182/blood-2022-159478

Published: 2022

Journal Articles

Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs

Blood (2022) 140 (Supplement 1): 10720–10721.

https://doi.org/10.1182/blood-2022-158808

Published: 2022

Journal Articles

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Blood (2021) 138 (Supplement 1): 2427.

https://doi.org/10.1182/blood-2021-145421

Published: 2021

Journal Articles

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Blood (2021) 138 (Supplement 1): 2641.

https://doi.org/10.1182/blood-2021-146848

Published: 2021

Journal Articles

Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial

Blood (2020) 136 (Supplement 1): 29–30.

https://doi.org/10.1182/blood-2020-137119

Published: 2020

Journal Articles

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab

Blood (2019) 134 (Supplement_1): 5485.

https://doi.org/10.1182/blood-2019-126717

Published: 2019

Journal Articles

External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

Blood (2019) 134 (Supplement_1): 4308.

https://doi.org/10.1182/blood-2019-126702

Published: 2019

Journal Articles

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Patrizia Mondello, MD PhD MSc, Irene Dogliotti, MD, Jan-Paul Bohn, Federica Cavallo, Simone Ferrero, MD, Barbara Botto, Claudio Cerchione, MD PhD, Davide Nappi, Sonya De Lorenzo, Giovanni Martinelli, MD, Dominik Wolf, Univ. Prof. Dr., Giacomo Loseto, MD, Salvatore Cuzzocrea, MD PhD, Wolfgang Willenbacher, MD PhD, Michael Mian, MD

Blood (2019) 134 (Supplement_1): 1565.

https://doi.org/10.1182/blood-2019-128198

Published: 2019

Journal Articles

Ibrutinib, Single Agent BTK Inhibitor, for Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: A Real-Life Experience from Rete Ematologica Pugliese (REP)

Potito Rosario Scalzulli, MD, Attilio Guarini, MD, Giacomo Loseto, MD, Giorgina Specchia, Anna Maria Giordano, Domenico Pastore, MD PhD, Giovanni Quintana, MD, Patrizio Mazza, MD, Alessandro Maggi, Nicola Di Renzo, MD, Maria Rosaria De Paolis, Giuseppe Tarantini, Gaetano De Santis, MD, Vincenzo Pavone, Antonino Greco, MD, Maria Rosa Valvano, Statistician, Nicola Cascavilla, MD

Blood (2018) 132 (Supplement 1): 5557.

https://doi.org/10.1182/blood-2018-99-116441

Published: 2018

Journal Articles

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Michele Merli, MD, Stefano Luminari, MD, Lucia Farina, Federica Cocito, MD, Irene Defrancesco, MD, Guido Gini, MD, Annalisa Arcari, MD, Greta Scapinello, MD, Massimo Gentile, MD, Maria Goldaniga, MD, Giacomo Loseto, MD, Emanuele Cencini, MD, Antonino Greco, MD, Andrea Ferrario, MD, Benedetta Bianchi, MD, Francesca Gaia Rossi, MD, Silvia Bolis, MD, Francesco Passamonti, MD, Luca Arcaini, MD

Blood (2018) 132 (Supplement 1): 2066.

https://doi.org/10.1182/blood-2018-99-113536

Published: 2018

Journal Articles

Mantle Cell Lymphoma Mimicking Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas: A Pathological Characterization (on behalf of the "Fondazione Italiana Linfomi (FIL) - Postgraduate Master Course")

Blood (2017) 130 (Supplement 1): 4049.

https://doi.org/10.1182/blood.V130.Suppl_1.4049.4049

Published: 2017

NARROW

Baseline Characteristics from CLL-ZANU2024, an Italian Non-Interventional Study Assessing the Real-World Use of Zanubrutinib in the Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)

Exploring the Cell-Free Transcriptome As Biomarker Source in IgM Gammopathies: New Insights from the Fondazione Italiana Linfomi “BIO-WM” Trial

Ibrutinib As First Line Therapy in Chronic Lymphocytic Leukemia Patients over 80 Years Old: A Retrospective Real-Life Multicenter Italian Cohort

Efficacy and Safety of Ibrutinib in Relapsed or Refractory Marginal Zone Lymphomas: The “Real World” Italian Experience

Brentuximab Vedotin in the Treatment of Cutaneuous T Cell Lymphomas: A Multicenter, Retrospective, Case-Control Study from Italy

Prospective Evaluation of Minimal Residual Disease in Waldenström Macroglobulinemia across Different Tissues and Treatments: Results of the “BIO-WM” Trial of the Fondazione Italiana Linfomi (FIL)

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Older Patients with Mantle Cell Lymphoma: A Phase 2 Study By the Fondazione Italiana Linfomi (FIL)

Real-World Venetoclax-Obinutuzumab in 232 Treatment Naive CLL Patients: Feasibility and Tolerability

Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure

A Digital Gene-Expression Signature Supports Mediastinal Gray Zone Lymphoma Stratification within Classical Hodgkin or Primary Mediastinal B-Cell Lymphoma

Validation of Argo (Automatic record generator for Onco-Hematology), a New App Supporting the Automatic Conversion of Paper-Based Pathology Reports in Standardized Ecrfs

Rituximab, Bendamustine and Cytarabine Followed By Venetoclax (V-RBAC) in High-Risk Elderly Patients with Mantle Cell Lymphoma

Efficacy of Front-Line Ibrutinib Versus Fludarabine, Cyclophosphamide and Rituximab (FCR) in Patients with CLL. a Multicenter "Real-World" Study

Characterization of B-Cell and Plasma Cell Compartment By Eight-Color Multiparameter Flow Cytometry in Patients with Waldenstrom Macroglobulinemia Prospectively Enrolled in the Fondazione Italiana Linfomi (FIL) BIO-WM Trial

Evaluation of the International Prognostic Index for Chronic Lymphocytic Leukemia (CLL-IPI) and Validation of a Proposed Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory (R/R) CLL Patients Receiving Idelalisib and Rituximab

External Validation of a Novel Risk Model (BALL Score) in Real-World Relapsed/Refractory Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. a Campus CLL Study

ABVD Versus Escalated Beacopp in Advanced Stage Hodgkin's Lymphoma: Results from a Retrospective, Multicenter European Study

Ibrutinib, Single Agent BTK Inhibitor, for Treatment Naïve (TN) and Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia: A Real-Life Experience from Rete Ematologica Pugliese (REP)

Pre-Treatment with Bendamustine Does Not Affect Stem Cell Mobilization in Patients with Indolent Non-Hodgkin Lymphomas: A Multicenter Study on Behalf of the Fondazione Italiana Linfomi

Mantle Cell Lymphoma Mimicking Mucosa-Associated Lymphoid Tissue (MALT) Lymphomas: A Pathological Characterization (on behalf of the "Fondazione Italiana Linfomi (FIL) - Postgraduate Master Course")

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only